Finally, we have investigated how the dose frequency and sequencing of clinically approved ET (Fulvestrant) and mTOR inhibitors (Everolimus) impact treatment efficacy in LBC. This evidence concerns the gene MTOR and CDH1-related diffuse gastric and lobular breast cancer syndrome.